BAUSCH HEALTH COS INC (BHC) Stock Price, Quote, News and Overview
NYSE:BHC - New York Stock Exchange, Inc. - CA0717341071 - Common Stock - Currency: USD
BHC Quote, Performance and Key Statistics
BAUSCH HEALTH COS INC
NYSE:BHC (2/13/2025, 9:59:50 AM)
6.36
0 (0%)
The current stock price of BHC is 6.36 USD. In the past month the price decreased by -14.97%. In the past year, price decreased by -25.26%.
BHC Latest News and Analysis
Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program
Bausch Health Provides Update on Strategic Alternatives
Tesla, Nvidia, GM And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
BHC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.53 | 833.45B | ||
| JNJ | JOHNSON & JOHNSON | 15.56 | 374.19B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 25.05 | 353.70B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.7 | 231.78B | ||
| MRK | MERCK & CO. INC. | 11.09 | 214.39B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.67 | 214.22B | ||
| PFE | PFIZER INC | 8.18 | 144.20B | ||
| SNY | SANOFI-ADR | 13.76 | 137.27B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 49 | 113.29B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 73.74B | ||
| ZTS | ZOETIS INC | 27.24 | 70.79B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 30.74 | 42.89B |
Related stock screener links
About BHC
Company Profile
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,270 full-time employees. The firm develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
Company Info
BAUSCH HEALTH COS INC
2150 St. Elzear Blvd. West
Laval QUEBEC H7L 4A8 CA
CEO: Joseph C. Papa
Employees: 20270
Company Website: https://www.bauschhealth.com/
Investor Relations: https://ir.bauschhealth.com
Phone: 18003611448
BHC FAQ
What is the stock price of BHC?
The current stock price of BHC is 6.36 USD.
What is the symbol for BAUSCH HEALTH COS INC stock?
The exchange symbol of BAUSCH HEALTH COS INC is BHC and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is BHC stock listed?
BHC stock is listed on the New York Stock Exchange, Inc. exchange.
Is BHC a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for BHC, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of BHC.
Does BHC stock pay dividends?
BHC does not pay a dividend.
When does BHC stock report earnings?
BHC will report earnings on 2025-02-19, after the market close.
What is the Price/Earnings (PE) ratio of BHC?
The PE ratio for BHC is 1.69. This is based on the reported non-GAAP earnings per share of 3.77 and the current share price of 6.36 USD.
What is the Short Interest ratio of BHC stock?
The outstanding short interest for BHC is 2.57% of its float.
BHC Technical Analysis
BHC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BHC. While BHC is still in line with the averages on profitability rating, there are concerns on its financial health.
BHC Financial Highlights
Over the last trailing twelve months BHC reported a non-GAAP Earnings per Share(EPS) of 3.77. The EPS decreased by 11.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.67% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BHC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 49% to BHC. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 9.43% and a revenue growth 11.48% for BHC